Qiagen (NYSE:QGEN) Sets New 12-Month Low - Should You Sell?

Key Points

• Qiagen shares hit a new 52‑week low at $33.78 (last $33.98), down about 10.8% on heavy volume.
• Management cut Q2 and full‑year guidance—Q2 EPS guided to ~0.60 (street ~0.62) and FY EPS to ~2.43 (street ~2.51)—and a shareholder investigation has introduced additional legal/uncertainty risk.
• Preliminary Q1 met adjusted EPS with roughly 2% reported sales growth, but management flagged weaker end‑markets (notably lower QuantiFERON demand); analysts on average rate the stock a "Hold" with a target near $53.64.

Qiagen N.V. (NYSE:QGEN - Get Free Report)'s share price hit a new 52-week low on Wednesday . The company traded as low as $33.78 and last traded at $33.9830, with a volume of 8088998 shares changing hands. The stock had previously closed at $38.09.

Qiagen News Summary

Here are the key news stories impacting Qiagen this week:

• Positive Sentiment: Preliminary Q1 results met adjusted diluted EPS outlook and reported net sales of about $492M (+2% reported), supporting near‑term profitability despite mixed sales trends. QIAGEN reports preliminary Q1 2026 results
• Neutral Sentiment: Unusually large options activity: traders bought ~6,107 call contracts on Monday (about +176% vs. average), indicating heightened speculative interest or hedging that can amplify intraday moves.
• Neutral Sentiment: Full Q1 earnings call transcript provides detail on end‑market weakness (lower QuantiFERON demand, cautious U.S. Life Sciences customers) and management’s rationale for the outlook. Qiagen N.V. (QGEN) Q1 2026 Earnings Call Transcript
• Neutral Sentiment: Analyst/industry writeups that deep‑dive into Q1 metrics are circulating; they summarize mixed product trends and longer‑term implications but do not add new company disclosures. Qiagen’s Q1 2026 Earnings Report: A Deep Dive into Financial Performance and Market Trends
• Negative Sentiment: Guidance cut: Q2 EPS guided to ~0.60 (street ~0.62) and Q2 revenue to ~$523.3M (street ~$554M). Full‑year 2026 EPS guided to ~2.43 (street ~2.51) and revenue to ~$2.1B (street ~$2.2B). These misses are the primary near‑term driver of downward pressure on the stock.
• Negative Sentiment: Shareholder investigation announced: law firm Johnson Fistel is investigating potential claims against Qiagen executives, which raises legal/uncertainty risk and can increase selling pressure. Qiagen N.V. Shareholders Are Encouraged to Reach Out to Johnson Fistel

Analysts Set New Price Targets

A number of brokerages recently weighed in on QGEN. JPMorgan Chase & Co. increased their price objective on shares of Qiagen from $55.00 to $60.00 and gave the company an "overweight" rating in a research report on Friday, February 6th. Jefferies Financial Group restated a "buy" rating and set a $59.00 price objective on shares of Qiagen in a research report on Thursday, February 5th. Barclays set a $44.00 price objective on shares of Qiagen and gave the company an "equal weight" rating in a research report on Tuesday, April 14th. Weiss Ratings restated a "hold (c)" rating on shares of Qiagen in a research report on Friday, March 27th. Finally, UBS Group set a $52.00 price objective on shares of Qiagen in a research report on Monday, February 9th. Four analysts have rated the stock with a Buy rating, six have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of "Hold" and an average target price of $53.64.

Qiagen Stock Down 10.8%

The company has a debt-to-equity ratio of 0.44, a current ratio of 3.90 and a quick ratio of 3.31. The firm has a market capitalization of $7.00 billion, a P/E ratio of 16.85, a P/E/G ratio of 1.97 and a beta of 0.79. The company's 50-day simple moving average is $42.37 and its two-hundred day simple moving average is $46.95.

Qiagen (NYSE:QGEN - Get Free Report) last released its quarterly earnings results on Wednesday, February 4th. The company reported $0.62 earnings per share for the quarter, topping the consensus estimate of $0.61 by $0.01. Qiagen had a net margin of 20.33% and a return on equity of 14.56%. The business had revenue of $540.42 million for the quarter, compared to the consensus estimate of $528.53 million. During the same period last year, the firm earned $0.61 earnings per share. The company's quarterly revenue was up 3.6% on a year-over-year basis. Qiagen has set its FY 2026 guidance at 2.500- EPS and its Q1 2026 guidance at 0.540- EPS. As a group, research analysts expect that Qiagen N.V. will post 2.5 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the business. Danske Bank A S bought a new position in Qiagen in the third quarter worth approximately $36,000. Smartleaf Asset Management LLC raised its position in Qiagen by 1,383.3% in the third quarter. Smartleaf Asset Management LLC now owns 890 shares of the company's stock worth $39,000 after acquiring an additional 830 shares during the period. Manchester Capital Management LLC bought a new position in Qiagen in the fourth quarter worth approximately $42,000. Global Retirement Partners LLC raised its position in Qiagen by 279.9% in the fourth quarter. Global Retirement Partners LLC now owns 1,155 shares of the company's stock worth $52,000 after acquiring an additional 851 shares during the period. Finally, Allworth Financial LP raised its position in Qiagen by 23.2% in the third quarter. Allworth Financial LP now owns 1,358 shares of the company's stock worth $61,000 after acquiring an additional 256 shares during the period. 70.00% of the stock is currently owned by institutional investors.

About Qiagen

Qiagen NV NYSE: QGEN is a global provider of sample and assay technologies designed to enable molecular testing in the fields of molecular diagnostics, applied testing, academic research and pharmaceutical development. The company's solutions span the full workflow of nucleic acid and protein analysis, offering customers standardized kits, instruments and software tools that streamline the preparation, detection and quantification of DNA, RNA and proteins.

The company's product portfolio includes nucleic acid extraction and purification systems, polymerase chain reaction (PCR) reagents and instrumentation, digital PCR platforms, next-generation sequencing (NGS) library‐preparation kits and proteomics solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.